EVALUATION OF OUTCOMES AND GENETIC PREDICTIVE FACTORS FOR PROGNOSIS AND TOXICITY IN HORMONE-REFRACTORY PROSTATE CANCER PATIENTS FOLLOWING COMBINATION THERAPY WITH DOCETAXEL, ESTRAMUSTINE, AND CARBOPLATIN

2009 ◽  
Vol 181 (4S) ◽  
pp. 293-293
Author(s):  
Shintaro Narita ◽  
Hiroshi Tsuruta ◽  
Mitsuru Saito ◽  
Teruaki Kumazawa ◽  
Yohei Horikawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Cancer Patients ◽  
Predictive Factors ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

Anticancer Effect of Combination Therapy of VP16 and Fosfesterol in Hormone-Refractory Prostate Cancer

2008 ◽  
Vol 31 (2) ◽  
pp. 188-194 ◽  
Author(s):  
Haruhito Azuma ◽  
Takeshi Sakamoto ◽  
Satoshi Kiyama ◽  
Takanobu Ubai ◽  
Yatsugu Kotake ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Hormone Refractory Prostate Cancer ◽  
Anticancer Effect ◽  
Hormone Refractory

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

Cancer ◽  
2007 ◽  
Vol 109 (6) ◽  
pp. 1090-1096 ◽  
Author(s):  
William K. Oh ◽  
Kevin Proctor ◽  
Mari Nakabayashi ◽  
Carolyn Evan ◽  
Lauren K. Tormey ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Renal Impairment ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory
Sign in / Sign up

Export Citation Format

Share Document